'Endpoints' presentation slideshows

CHORD LENGTH PARAMETERIZATION

CHORD LENGTH PARAMETERIZATION. ??? 2008.10.30. CHORD LENGTH PARAMETERIZATION. Chord length:. CHORD LENGTH PARAMETERIZATION. A curve is said to be chord-length parameterized if chord (t) = t.

491 views • 34 slides

Analysis of Multiple End Points in Clinical trials

460 views • 27 slides

Outcome/ instruments selection

Outcome/ instruments selection. Wei-Chu Chie Preventive Medicine. A review of outcomes. Clinical Death: binary/Disease: any type/Utilization of care Functional/QOL Discomfort, QOL/Disability Perceptual Dissatisfaction/satisfaction, QOL Financial Behavioral

431 views • 27 slides

Validation Plan for the EDSP Mammalian Tier 2 Assay

Validation Plan for the EDSP Mammalian Tier 2 Assay. Presentation to the Endocrine Disruptor Methods Validation Subcommittee June 6, 2003 J. Kariya. Overview of presentation. Validation plan Concerns Questions for EDMVS. Validation plan.

324 views • 18 slides

Estimating Maximal Information Amount under Interval Uncertainty

Gang Xiang Philips Electronics Healthcare Informatics Business Group gxiang@acm.org. Estimating Maximal Information Amount under Interval Uncertainty. Measure of Uncertainty. Uncertainty: we know n possible states. Measure of uncertainty:

295 views • 18 slides

Dynamic Ham-Sandwich Cuts of Convex Polygons in the Plane

Dynamic Ham-Sandwich Cuts of Convex Polygons in the Plane. Jelani Nelson Vincent Yeung. (Based on paper co-authored with Timothy Abbott, Erik D. Demaine, Martin L. Demaine, Daniel Kane, Stefan Langerman). Ham-Sandwich Cuts. Sets of red points R and green points G .

274 views • 15 slides

Translation Pathway for Coronary Stent Development- Clinical Endpoints

Translation Pathway for Coronary Stent Development- Clinical Endpoints. Donald E. Cutlip, MD Beth Israel Deaconess Medical Center Baim Institute for Clinical Research Harvard Medical School. Disclosure Statement of Financial Interest.

383 views • 13 slides

Orthopedic Outcomes Measures for NF

360 views • 13 slides

Offers GLP preclinical and biology CRO services:

Altogen Labs Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery & Therapeutics. Offers GLP preclinical and biology CRO services: Xenograft mice services-drug discovery and drug development Pharmacology and toxicology testing (IND)

405 views • 11 slides

Windows Communication Foundation Hosting & Endpoints Winter 2006

Windows Communication Foundation Hosting & Endpoints Winter 2006. WCF Hosting & Endpoints. Agenda Address, Binding, Contract & Hosting WCF Endpoints Architecture Hosting Options basicHttpBinding Demo netTcpBinding & netMsmqBinding Demo. About Me.

194 views • 9 slides

CHAPTER 2

The Definite Integral. CHAPTER 2. 2.4 Continuity. f ( x ). ? x. x i. x i+1. x i *. ? i=1 n f ( x i * ) ? x. Riemann Sum. animation.

196 views • 8 slides

TAXUS II and IV: two-year follow-up

TAXUS II and IV: two-year follow-up. TAXUS IV Trial. TAXUS II Trial. 1,326 patients with single de novo lesions Lesions 10-28 mm in length, 2.5-3.75 mm in diameter; Double blind, randomized trial. 536 patients with single de novo lesions Lesions < 12 mm in length, 3.0-3.5 mm in diameter;

244 views • 7 slides

NAT Diagnostics

NAT Diagnostics. Derek MacDonald. Overview. NAT type discovery was defined in 3489 Was not included in 3489bis as the discovery mechanism is not accurate A reduced mechanism may be useful as a diagnostic tool Could be useful to optimize P2P applications. Problems from 3489.

237 views • 7 slides

ARTS-II Trial

ARTS-II Trial. Arterial Revascularization Therapies Part II: a non-randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with multi-vessel coronary artery lesions. Presented at The American College of Cardiology 2005. ARTS-II Trial.

361 views • 6 slides

Continuous Positive Airway Pressure for Heart Patients with Central Sleep Apnea

CANPAP. Continuous Positive Airway Pressure for Heart Patients with Central Sleep Apnea. Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. T. Douglas Bradley. CANPAP.

239 views • 6 slides

Pioglitazone Reduces Neointima Formation After Coronary Stent Implantation

Pioglitazone Trial. Pioglitazone Reduces Neointima Formation After Coronary Stent Implantation . Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. Nikolaus Marx. Piaglitazone Trial. 50 nondiabetic patients undergoing PCI in de novo lesions

239 views • 6 slides

Switch to ATV-containing regimen - ARIES - INDUMA - ASSURE

171 views • 6 slides

STRATEGY Trial

STRATEGY Trial. Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction . Journal of the American Medical Association May 4, 2005 Marco Valgimigli , et al. . STRATEGY Trial. 175 patients with STEMI or new left bundle-branch block

196 views • 5 slides

Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy

SAPPHIRE Trial. Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy. Presented by Jay Yadav, MD on behalf of the SAPPHIRE Investigators AHA 2002. SAPPHIRE. 723 patients with high risk for CEA > 50% stenosis in symptomatic patients

407 views • 4 slides

DIABETES trial

DIABETES trial. 149 patients with type 2 diabetes (1/3 on insulin) and native coronary lesions appropriate for stent implantation . Cypher sirolimus-eluting stent. Bare-metal stent. Primary Endpoint: In-stent and late lumen loss at 9 months (determined by QCA) Secondary Endpoints:

186 views • 4 slides